Seeking Alpha

Corcept Therapeutics (CORT -8.7%) sinks on heavy volume, despite regulators accepting its...

Corcept Therapeutics (CORT -8.7%) sinks on heavy volume, despite regulators accepting its application to market Corlux as a treatment for Cushing's Syndrome. After final approval, Corcept will have seven years to market the drug exclusively.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)